|
|
| CYTK (NASDAQ) - CYTOKINETICS INC | |
pop up description layer
Active Signal: SELL (since 2010-08-06)| Most Recent | Close | Change | | 2010-09-03 | $2.30 | $0.03 (1.32%)  |
|
You need to upgrade your Flash Player
Internet Stock Research Resources
| |  Company Website | |  Public Information |
| Latest News | |  MSN Stock Rating |
 Stock Charts | |  BarChart |
| Yahoo Msg Board | |  Motley Fool |
| | | Company News | | | - Cytokinetics to Present at Canaccord Genuity Global Growth Conference
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 08/04/10 --
Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that Robert
I. Blum, President and Chief Executive Officer, is scheduled to
present a corporate update at the Canaccord Genuity 30th Annual
Global Growth Conference 2010 on Wednesday, August 11th at 10:30 a.m.
Eastern Daylight Time at the InterContinental Hotel in Boston,
Massachusetts.
Interested parties may access the live audio webcast of this
presentation and replay by visiting the Investor Relations section of
the Cytokinetics website at www.cytokinetics.com. The webcast replay
of these presentations will be archived on the Presentations page
within the Investor Relations section of Cytokinetics' website for
two weeks following the completion of the event.
- Cytokinetics, Incorporated Reports Second Quarter 2010 Financial Results
Company Reports on Progress of Drug Candidates in Clinical Trials;
Interim Review of Data From Phase IIa Evidence of Effect Trial in ALS
Patients Supports Continuation
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 07/28/10 -- Cytokinetics,
Incorporated (NASDAQ: CYTK) reported revenues from research and
development collaborations of $0.5 million for the second quarter of
2010. The net loss for the second quarter was $13.1 million, or $0.21
per basic and diluted share. This compared to a net income of $56.0
million, or $0.99 and $0.98 per basic and diluted share,
respectively, for the same period in 2009. As of June 30, 2010, cash,
cash equivalents and investments, excluding restricted cash, totaled
$87.6 million.
- Cytokinetics Announces Award of Grant for Preclinical and Clinical Development of CK-2017357 in Myasthenia Gravis
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 07/26/10 --
Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that the
National Institute of Neurological Disorders and Stroke (NINDS) has
awarded the company a grant in the amount of $2.9 million to support
research and development of CK-2017357, a fast skeletal muscle
troponin activator, directed to the potential treatment for
myasthenia gravis. The grant was awarded to Cytokinetics under the
American Recovery and Reinvestment Act of 2009.
"We are pleased to receive this award which affords us the
opportunity to further investigate CK-2017357 as a potential
treatment for patients with myasthenia gravis. With this funding, we
intend to conduct further preclinical research which may support the
initiation of a third Phase IIa Evidence of Effect clinical trial
with this novel drug candidate. This third trial would be in addition
to the two Phase IIa trials now underway, one in patients with
amyotrophic lateral sclerosis and the other in patients with
claudication associated with peripheral artery disease," stated
Robert I. Blum, President and CEO, Cytokinetics. "This grant serves
as further evidence of Cytokinetics' commitment to broadly
investigate the pharmacology of skeletal muscle activators and
recognizes the innovation and promise of our biopharmaceutical
discovery and development activities."
- Cytokinetics Announces Presentation of Phase I Data Relating to CK-2017357 at the XII International Congress on Neuromuscular Diseases
Results Demonstrate that Novel Mechanism of Company's Fast Skeletal
Muscle Troponin Activator Translates to Potentially Clinically
Relevant Effects on Muscle Performance in Humans
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 07/22/10 --
Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that a
poster summarizing data from a Phase I clinical trial of CK-2017357,
a novel fast skeletal muscle troponin activator, was presented in the
Late Breaking News Poster Presentation Session at the XII
International Congress on Neuromuscular Diseases, which was held July
17-22, 2010 at the Centro Congressi, Universita degli Studi di Napoli
Federico II, in Naples, Italy.
- Cytokinetics to Announce Second Quarter Results on July 28, 2010
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 07/21/10 --
Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that it is
scheduled to report second quarter results on Wednesday, July 28,
2010 at 4:00 p.m. Eastern Time. Following the announcement,
Cytokinetics' senior management will host a conference call at 4:30
p.m. Eastern Time to discuss operational and financial results and
the company's outlook for the future.
The conference call will be simultaneously webcast and can be
accessed in the Investor Relations section of Cytokinetics' website
at www.cytokinetics.com. The live audio of the conference call is
also accessible via telephone by dialing either (866) 999-CYTK (2985)
(United States and Canada) or (706) 679-3078 (International) and
typing in the passcode 53716226.
- Cytokinetics to Present Phase I Data Relating to CK-2017357 at the XII International Congress on Neuromuscular Diseases
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 07/14/10 --
Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that a
poster summarizing Phase I data relating to CK-2017357 is scheduled
to be presented in the Late Breaking News Poster Presentation Session
at the XII International Congress on Neuromuscular Diseases to be
held July 17-22, 2010 at the Congress Venue Ateneo Federico II, Monte
S. Angelo University Campus in Naples, Italy.
CK-2017357, the lead drug candidate from the company's skeletal
muscle contractility program, is a fast skeletal muscle troponin
activator and is in Phase IIa clinical trials. CK-2017357 selectively
activates the fast skeletal muscle troponin complex and increases its
sensitivity to calcium, leading to an increase in skeletal muscle
force. This mechanism of action has demonstrated pharmacological
activity in preclinical models that may relate to the potential
treatment of diseases associated with aging, muscle wasting or
neuromuscular dysfunction.
- More CYTK News..
| |
|
|
|
|
InvestSignal.com: Discovering Stock Market Opportunities Every Day.
HOME ||
Terms of Use || Privacy Policy || FAQ
|| Contact Us
Copyright © 2009-2010 InvestSignal.com. All rights reserved.
Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI).
TERMS OF USE: The materials provided on this site is for informational purposes only, and no mention of a particular security constitutes a recommendation to buy, sell,
or hold that or any other security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.
InvestSignal.com and its publishers cannot and do not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability
or profitability of any particular investment, or the potential value of any investment or informational source. You, the reader, are solely responsible for
your own investment research and decisions, and should seek the advice of qualified licensed investment and tax professionals before making any investment.
This site represents opinions of the authors and is not in any way affiliated with any companies listed. InvestSignal.com, its publishers or the authors
shall not be liable for any factual errors in the content or for any actions taken in reliance thereon. InvestSignal.com, its publishers and the authors may
hold positions in any of the securities listed. Use of this website equals to your agreement with these terms without any conditions.
|
